Clarifying the Optimal Application of SLT Therapy Trial

Prior treatment

• Use of topical IOP-lowering medications for more than 6 cumulative months at any time in the past 5 years (this is a modification implemented during active enrollment)
• Any intraocular surgical procedure within the past 6 months in either eye

Other illness

• Any history of IOP-lowering laser (prophylactic iridotomy not included) or surgical procedure

Other

• Advanced POAG in either eye (worse than moderate POAG as defined above)
• Glaucoma other than POAG (including pigmentary and pseudoexfoliation glaucoma) in either eye
• Mean IOP \> 35 mmHg at either the screening or baseline visit in either eye
• Narrow or closed angle (Shaffer Grade 0, 1, or 2) in either eye
• Contraindications to SLT or any other study intervention
• Any corneal pathology that would preclude accurate assessment of IOP by Goldmann tonometry in either eye
• Inability to attend all scheduled study visits
• Pregnant or planning to become pregnant in the next 4 years

• Age 18 or older and in good health
• Each eye with one of the following qualifying diagnoses (diagnoses may differ between eyes):
  • High-risk ocular hypertension (OHT): IOP \> 21 mmHg without glaucomatous optic neuropathy (excavation, diffuse or focal thinning or notching of the neuroretinal rim, visible nerve fiber layer defects, or asymmetry of the vertical cup-to-disc ratio of \>0.2 between eyes)
  • Mild primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation better than -6.0 dB with no points in the central 5° \<15 dB (see figure on next page)
  • Moderate primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5° points \<15 dB or mean deviation -12.0 dB or better with 1 central 5° points \<15 dB (see figure on next page).
• Each eye with BCVA 20/200 (UK 6/60) or better